Form 4: Quest Diagnostics Executive Kuppusamy Reports Stock Transactions
SEC Form 4 Filing
Karthik Kuppusamy, SVP at Quest Diagnostics, reports acquisition and disposal of company stock related to vesting of restricted stock units and a performance stock award.
Summary
- Karthik Kuppusamy, a Senior Vice President at Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On March 3, 2025, Kuppusamy disposed of 992 shares of common stock at $173.74 per share to cover tax withholding obligations from vesting restricted stock units.
- On March 4, 2025, Kuppusamy acquired 4,434 shares of common stock at $173.74 per share related to a performance stock award.
- Also on March 4, 2025, Kuppusamy disposed of 1,879 shares at $173.74 per share to cover tax withholding obligations from the settlement of the performance share award.
- Following these transactions, Kuppusamy directly owns 13,119 shares of common stock.
- Kuppusamy also indirectly owns 358 shares through a trust and 1,594 shares through a 401(k) plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are related to compensation and tax obligations, which are standard practices. The performance stock award suggests positive performance, but the filing itself is purely informational.
Positives
- The acquisition of 4,434 shares indicates a positive performance stock award payout.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive stock transactions are common across publicly traded companies, and the reporting requirements are standardized by the SEC.
- Similar filings can be observed for executives at comparable companies in the diagnostic testing industry, such as Laboratory Corporation of America Holdings (LH) and Bio-Rad Laboratories (BIO).
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Disposition of 992 shares to cover tax withholding obligations. |
| 03/04/2025 | Acquisition of 4,434 shares related to a performance stock award and disposition of 1,879 shares to cover tax withholding obligations. |
| 03/05/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.